Liver Fibrosis: From Pathogenesis to Novel Therapies
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Chronic liver injury is accompanied by a dysbalanced scarring process, termed fibrosis. This process is mainly driven by chronic inflammation and an altered activity of a multitude of different chemokines and cytokines, resulting in the infiltration by immune cells (especially macrophages) and increase of matrix-expressing cell types. These processes might lead to cirrhosis representing the end-stage of fibrosis. Recent clinical studies comprising patients successfully treated for viral hepatitis showed that liver fibrogenesis and even cirrhosis may be reverted. The hepatic capacity to remodel scar tissue and to revert into a normal liver follows specific mechanistic principles that include the termination of chronic tissue damage, shifting the cellular bias from inflammation to resolution, initiation of myofibroblast apoptosis or senescence and, finally, fibrinolysis of excess scar tissue. The plurality of molecular and cellular triggers involved in initiation, progression and resolution of hepatic fibrogenesis offers an infinite number of therapeutic possibilities. For instance, inflammatory macrophages can be targeted via inhibition of chemokine CCL2 or its receptor CCR2 (e.g., by cenicriviroc) as well as by transfer of restorative macrophage subsets. Another target is galectin-3 that acts at various stages along the continuum from acute to chronic inflammation. Profibrogenic cytokines (e.g., transforming growth factor-β), matricellular proteins (e.g., CCN1/CYR61) or signaling pathways involved in fibrogenesis offer further possible targets. Other options are the application of therapeutic antibodies directed against components involved in biogenesis or remodeling of connective tissue such as lysyl oxidase-like-2 or synthetic bile acids like obeticholic acid that activate the farnesoid X receptor and was antifibrotic in a phase 2 study (FLINT trial). Factors affecting the gut barrier function or the intestinal microbiome further expanded the repertoire of drug targets. In this review, we discuss novel concepts in resolution of hepatic fibrosis and focus on drug targets that might be suitable to trigger resolution of fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Alterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061
Self-citationHepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Cited by
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Self-citationTargeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Self-citationTGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
Self-citationLiver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
Zhang, C.-Y., Yuan, W.-G., He, P., Lei, J.-H., & Wang, C.-X. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10512 · Cited by 594
Krenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557
Self-citationOrgan and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Self-citationThrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
Murphy-Ullrich, J. E., & Suto, M. J. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.009 · Cited by 332
Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
Cai, B., Dongiovanni, P., Corey, K. E., Wang, X., Shmarakov, I. O., Zheng, Z., Kasikara, C., Davra, V., Meroni, M., Chung, R. T., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.013 · Cited by 266
Krenkel, O., Hundertmark, J., Ritz, T., Weiskirchen, R., & Tacke, F. (2019) · Cells · doi:10.3390/cells8050503 · Cited by 241
“, neutrophils via CXCL1 and monocytes via CCL2, which has been linked to exacerbated hepatic inflammation [3].”
Self-citationMacrophages in nonalcoholic fatty liver disease: a role model of pathogenic immunometabolism
Krenkel, O., & Tacke, F. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1604480 · Cited by 66
Self-citationRoles of Macrophages and Exosomes in Liver Diseases
Shen, M., Shen, Y., Fan, X., Men, R., Ye, T., & Yang, L. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.583691 · Cited by 61
Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126696 · Cited by 59
Self-citationKohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
Self-citationIwata, A., Maruyama, J., Natsuki, S., Nishiyama, A., Tamura, T., Tanaka, M., Shichino, S., Seki, T., Komai, T., Okamura, T., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06357-5 · Cited by 25
Metadata
- Authors
- Weiskirchen, R., & Tacke, F.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 34
- Issue
- 4
- Pages
- 410-422
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2363023549
- Cited by
- 156
- References
- 30
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.